Page 20 - Diagnostics Division News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Avacta Group is developing novel cancer immunotherapies and powerful diagnostics based on its two proprietary platforms - Affimer ® biologics and pre|CISION™ tumour targeted chemotherapies.   The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets, such as diagnostics and therapeutics, worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken to generate new antibodies and the reliance ...

F. Hoffmann-La Roche Ltd: Roche reports solid results in 2020 Group sales increase 1% 1 at constant exchange rates (CER); 5% decline in Swiss francs, as a result of continued appreciation of the Swiss franc against most currencies Pharmaceuticals Division sales decline 2%; continued strong sales growth of newly launched medicines (+32% 2, including Tecentriq, Hemlibra, Ocrevus, Perjeta and Kadcyla) largely offsets the impact of competition from biosimilars (CHF -5.1 billion at CER 3), but not the additional COVID-19-related impact from missed medical appointments Diagnostics Division sales gr...